Skip to main content
SpringerLink
Log in

Medikamentöse Therapie des Morbus Crohn

  • Chapter
Morbus Crohn - Colitis ulcerosa

  • 113 Accesses

Zusammenfassung

Morbus Crohn ist eine chronisch-entzündliche Darmerkrankung ungeklärter Ätiologie, die durch keine konservative oder chirurgische Maßnahme zu heilen ist. Die medikamentöse Therapie des Morbus Crohn hat das Ziel, durch Verringerung der Entzündungsaktivität die klinische Symptomatik zu verbessern, die Lebensqualität des Patienten zu steigern und das Auftreten von rezidivierenden Schüben zu verhindern. Es werden zunächst die Erfahrungen mit den verschiedenen Substanzen in der Therapie des Morbus Crohn diskutiert und schließlich praktische Therapieempfehlungen (s. Abschn. 17.10) gegeben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Therapie des aktiven Morbus Crohn mit Glukokortikoiden

  • Felder JB, Adler DJ, Korelitz BI (1991) The safety of corticosteroid therapy in Crohn’s disease with an abdominal mass. Am J Gastroenterol 86: 1450–1455

    PubMed  CAS  Google Scholar 

  • Greenberg GR, Feagan BG, Martin F et al. (1994) Oral budesonide for active Crohn’s disease. N Engl J Med 331: 836–841

    Article  PubMed  CAS  Google Scholar 

  • Landi B, N’Guyen Anh T, Cortot A et al. (1992) Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. Gastroenterology 102: 1647–1653

    PubMed  CAS  Google Scholar 

  • Malchow H, Ewe K, Brandes JW et al. (1984) European cooperative Crohn’s disease study (ECCDS): Results of drug treatment. Gastroenterology 86: 249–266

    PubMed  CAS  Google Scholar 

  • Modigliani R, Mary JY, Simon JF et al. (1990) Clinical, biological and endoscopic picture of attacks of Crohn’s disease. Gastroenterology 98: 811–818

    Article  PubMed  CAS  Google Scholar 

  • Novacek G, Kleinberger M, Vogelsang H et al. (1995) Budesonide in glucocorticoid dependent chronic active Crohn’s disease; a pilot study. Z Gastroenterol 33: 251–254

    PubMed  CAS  Google Scholar 

  • Rutgeerts P, Löfberg R, Malchow H et al. (1994) A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 331: 842–845

    Article  PubMed  CAS  Google Scholar 

  • Summers RW, Switz DM, Sessions JT Jr et al. (1979) National cooperative Crohn’s disease study: Results of drug treatment. Gastroenterology 77: 847–869

    PubMed  CAS  Google Scholar 

  • Wright JP, Jarnum S, Schaffalitzky de Muckadell O et al. (1993) Oral fluticasone propionate compared with prednisolone in treatment of active Crohn’s disease: a randomized doubleblind multicentre study. Eur J Gastroenterol Hepatol 5: 499–503

    Google Scholar 

Sulfasalazin und Aminosalizylate in der Therapie des aktiven Morbus Crohn

  • Gross V, Andus T, Fischbach W et al. (1995) Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn’s ileocolitis. A multicenter randomized double-blind study. Z Gastroenterol 33: 581–584

    PubMed  CAS  Google Scholar 

  • Martin F, Sutherland L, Beck IT et al. (1990) Oral 5-ASA versus prednisone in short term treatment of Crohn’s disease: a multicentre controlled trial. Can J Gastroenterol 4: 452–457

    Google Scholar 

  • Rijk MCM, Hogezand RA van, Lier HJJ van et al. (1991) Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. Ann Intern Med 114: 445–450

    PubMed  CAS  Google Scholar 

  • Singleton JW, Hanauer SB, Gitnick GL et al. (1993) Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Gastroenterology 104: 1293–1301

    PubMed  CAS  Google Scholar 

  • Singleton JW, Hanauer S, Robinson M (1995) Quality-of-life results of double-blind, placebocontrolled trial of mesalamine in patients with Crohn’s disease. Dig Dis Sei 40: 931–935

    Article  CAS  Google Scholar 

  • Tremaine WJ, Schroeder KW, Harrison JM et al. (1994) A randomized, double-blind, placebocontrolled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s Colitis and ileocolitis. J Clin Gastroenterol 19: 278–282

    Article  PubMed  CAS  Google Scholar 

Azathioprin und 6-Mercaptopurin

  • Candy S, Wright J, Gerber M et al. (1995) A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 27: 674–678

    Article  Google Scholar 

  • Colonna T, Korelitz BI (1994) The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn’s disease. Am J Gastroenterol 89: 362–366

    PubMed  CAS  Google Scholar 

  • Ewe K, Press AG, Singe CC et al. (1993) Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 105: 367–372

    PubMed  CAS  Google Scholar 

  • O’Brien JJ, Bayless TM, Bayless JA (1991) Use of Azathioprine or 6-mercaptopurine in the treatment of Crohn’s disease. Gastroenterology 101: 39–46

    PubMed  Google Scholar 

  • Pearson DC, May GR, Fick GH (1995) Azathioprine and 6-Mercaptopurine in Crohn disease. Ann Intern Med 122: 132–142

    Google Scholar 

Cyclosporin

  • Brynskov J, Freund L, Norby Rasmussen S et al. (1989) A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N Engl J Med 321: 845–850

    Article  PubMed  CAS  Google Scholar 

  • Brynskov J, Freund L, Norby Rasmussen S et al. (1991) Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn’s disease. Scand J Gastroenterol 26: 689–695

    Article  PubMed  CAS  Google Scholar 

  • Feagan BG, McDonald JWD, Rochon J et al. (1994) Low-dose cyclosporine for the treatment of Crohn’s disease. N Engl J Med 330: 1846–1851

    Article  PubMed  CAS  Google Scholar 

  • Jewell DP, Lennard-Jones JE et al. (1994) Oral cyclosporin for chronic active Crohn’s disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 6: 499–505

    Article  Google Scholar 

  • Nicholls S, Domizio P, Williams CB et al. (1994) Cyclosporin as initial treatment for Crohn’s disease. Arch Dis Childh 71: 243–247

    Article  PubMed  CAS  Google Scholar 

  • Santos JV, Baudet JA, Casellas FJ et al. (1995) Intravenous cyclosporine for steriod-refractory attacks of Crohn’s disease. J Clin Gastroenterol 20: 207–210

    Article  PubMed  CAS  Google Scholar 

  • Stange EF, Modigliani R, Salvador Pena A et al. (1995) European trial of cyclosporine in chronic active Crohn’s disease: a 12-month study. Gastroenterol 109: 774–782

    Article  CAS  Google Scholar 

Metronidazol und andere Antibiotika

  • Kruiningen HJ van (1995) On the use of antibiotics in Crohn’s disease. J Clin Gastroenterol 20: 310–316

    Article  PubMed  Google Scholar 

  • Peppercorn MA (1993) Is there a role for antibodies as primary therapy in Crohn’s ileitis? J Clin Gastroenterol 17: 235–237

    Article  PubMed  CAS  Google Scholar 

  • Prantera C, Kohn A, Mangiarotti R et al. (1994) Antimycobacterial therapy in Crohn’s disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 89: 513–518

    PubMed  CAS  Google Scholar 

  • Sutherland L, Singleton J, Sessions J et al. (1991) Double-blind, placebo controlled trial of metronidzaole in Crohn’s disease. Gut 32: 1071–1075

    Article  PubMed  CAS  Google Scholar 

  • Swift GL, Srivastava ED, Stone R et al. (1994) Controlled trial of anti-tuberculous chemotherapy for two years in Crohn’s disease. Gut 35: 363–368

    Article  PubMed  CAS  Google Scholar 

  • Ursing B, Alm T, Barany F et al. (1982) A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: The cooperative Crohn’s disease study in Sweden. Gastroenterology 83: 550–562

    PubMed  CAS  Google Scholar 

Parenterale und enterale Ernährung

  • Bowling TE, Jameson JJ, Grimble GK et al. (1993) Enterai nutrition as a primary therapy in active Crohn’s disease. Eur J Gastroenterology Hepatol 5: 1–7

    Google Scholar 

  • Fernández-Banares F, Cabre E, González-Huix F et al. (1994) Enterai nutrition as primary therapy in Crohn’s disease. Gut (Suppl 1) S55–S59

    Google Scholar 

  • Griffiths AM, Ohisson A, Sherman PM et al. (1995) Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology 108: 1056–1067

    Article  PubMed  CAS  Google Scholar 

  • González-Huix F, Léon R de, Fernández-Banares F et al. (1993) Crohn’s disease: no longer feeding by bits and pieces? Gut 34: 778–782

    Article  PubMed  Google Scholar 

  • Gorard DA, Hunt JB, Payne-James JJ et al. (1993) Initial response and subsequent course of Crohn’s disease treated with elemental diet or prednisolone. Gut 34: 1198–1202

    Article  PubMed  CAS  Google Scholar 

  • Holdsworth D, Mansfield J (1994) Nutrition - support or specific therapy? Eur J Gastroenterol Hepatol 6: 93–99

    Google Scholar 

  • Lochs H, Steinhardt HJ, Klaus-Wentz B et al. (1991) Comparison of enteral nutrition and drug treatment in active Crohn’s disease. Gastroenterology 101: 881–888

    PubMed  CAS  Google Scholar 

  • Malchow H, Steinhardt HJ, Lorenz-Meyer H et al. (1990) Feasibility and effectiveness of a defined-formula diet regimen in treating active Crohn’s disease. Scand J Gastroenterol 25: 235–244

    PubMed  CAS  Google Scholar 

  • Mansfield JC, Giaffer MH, Holdsworth CD (1995) Controlled trial of Oligopeptide versus amino acid diet in treatment of active Crohn’s disease. Gut 36: 60–66

    Article  PubMed  CAS  Google Scholar 

  • Middleton SJ, Riordan AM, Hunter (1991) Comparison of ele mental and peptide-based diets in treatment of acute Crohn’s disease. Ital J Gastroenterol 34: 609A

    Google Scholar 

  • O’Morain C, Segal AW, Levi AJ (1984) Elemental diet as primary treatment of acute Crohn’s disease: a controlled trial. BMJ 288: 1859–1862

    Article  PubMed  Google Scholar 

  • Park HR, Galloway A, Danesh JZD et al. (1992) Double-blind controlled trial of elemental and Polymerie diets as primary therapy in active Crohn’s disease. Eur J Gastroenterol Hepatol 3: 483–490

    Google Scholar 

  • Raouf AH, Hildrey V, Daniel J et al. (1991) Enteral feeding as sole treatment for Crohn’s disease: controlled trial of whole protein v amino acid based feed and a case study of dietary challenge. Gut 32: 702–707

    Article  PubMed  CAS  Google Scholar 

  • Rigaud D, Cosnes J, LeQuintrec Y et al. (1991) Controlled trial comparing two types of enteral nutrition in treatment of active Crohn’s disease. Gut 32: 1492–1497

    Article  PubMed  CAS  Google Scholar 

  • Riordan AM, Hunter JO, Cowan RE et al. (1993) Treatment of active Crohn’s disease by exclusion diet: East Anglian multicentre controlled trial. Lancet 342: 1131–1134

    Article  PubMed  CAS  Google Scholar 

  • Royall D, Jeejeebhoy KN, Baker JP et al. (1994) Comparison of amino acid v peptide based enteral diets in active Crohn’s disease: clinical and nutritional outcome. Gut 35: 783–787

    Article  PubMed  CAS  Google Scholar 

  • Seidman E, LeLeiko N, Ament M et al. (1991) Nutritional issues in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 12: 424–438

    Article  PubMed  CAS  Google Scholar 

  • Seidman EG, Lohoues MJ, Turgeon J et al. (1991) Elemental diet versus prednisone as initial therapy in Crohn’s disease: early and long-term results. Gastroenterology 100: 250A

    Google Scholar 

  • Sitzmann JV, Converse RL jr, Bayless TM (1990) Favorable response to parenteral nutrition and medical therapy in Crohn’s Colitis. Gastroenterology 99: 1647–1652

    PubMed  CAS  Google Scholar 

  • Stange EF, Schmid U, Fleig WE et al. (1990) Ausschlußdiät bei Morbus Crohn: Eine kontrollierte, randomisierte Studie. Z Gastroenterol 28: 561–564

    PubMed  CAS  Google Scholar 

  • Wu S, Craig RM (1995) Intense nutritional support in inflammatory bowel disease. Dig Dis Sei 40: 843–852

    Article  CAS  Google Scholar 

Verschiedene Therapieansätze

  • Baron TH, Truss CD, Elson CO (1993) Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig Dis Sei 38: 1851–1856

    Article  CAS  Google Scholar 

  • Feagon BG, Rochon J, Fedorak RN et al. (1995) Methotrexate for the treatment of Crohn’s disease. N Engl J Med 332: 292–297

    Article  Google Scholar 

  • Hudson M, Wakefield AJ, Hutton RA et al. (1993) Factor XIIIA subunit of Crohn’s disease. Gut 34: 75–79

    Article  PubMed  CAS  Google Scholar 

  • Kozarek RA, Patterson DJ, Gelfand MD (1989) Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 110: 353–356

    PubMed  CAS  Google Scholar 

  • Levine DS, Fischer SH, Christie DL et al. (1992) Intravenous Immunglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn’s Colitis. Am J Gastroenterol 87: 91–100

    PubMed  CAS  Google Scholar 

Remissionserhaltung und Rezidivprophylaxe

  • Bello C, Goldstein F, Thornton JJ et al. (1991) Alternate-day Prednisone treatment and treatment maintenance in Crohn’s disease. Am J Gastroenterol 86: 460–466

    PubMed  CAS  Google Scholar 

  • Brignola C, Cottone M, Pera A et al. (1995) Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn’s disease. Gastroenterology 108: 345–349

    Article  PubMed  CAS  Google Scholar 

  • Caprilli R, Andreoli A, Capurso L et al. (1994) Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn’s disease. Aliment Pharmacol Ther 8: 35–43

    Article  PubMed  CAS  Google Scholar 

  • Ewe K, Herfarth C, Malchow H et al. (1989) Postoperative recurrence of Crohn’s disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 42: 224–232

    Article  PubMed  CAS  Google Scholar 

  • Gendre J-P, Mary J-Y, Florent C et al. (1993) Oral mesalamine (Pentasa) as maintenance treatment in Crohn’s disease: a multicenter placebo-controlled study. Gastroenterology 104: 435–439

    PubMed  CAS  Google Scholar 

  • Löfberg R, Rutgeerts P, Malchow H et al. (1994) Budesonide CIR for maintenance of remission in ileocecal Crohn’s disease. A European multi centre placebo-controlled trial for 12 months. Gastroenterology 106: A274

    Google Scholar 

  • McLeod RS, Wolff BG, Steinhart AH et al. (1995) Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn’s disease. Gastroenterology 109: 404–413

    Article  PubMed  CAS  Google Scholar 

  • Messori A, Brignola C, Trallori G et al. (1994) Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: a meta-analysis. Am J Gastroenterol 89: 692–698

    PubMed  CAS  Google Scholar 

  • Munkholm P, Langholz E, Davidsen M et al. (1994) Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 35: 360–362

    Article  PubMed  CAS  Google Scholar 

  • Pearson DC, May GR, Fick GH et al. (1995) Azathioprine and 6-mercaptopurine in Crohn disease. Ann Intern Med 122: 132–142

    Google Scholar 

  • Poulsen TD, Thornberg KJ, Olesen M-B et al. (1993) Perioperative blood transfusion and clinical recurrence in Crohn’s disease. Eur J Gastroenterol Hepatol 5: 835–838

    Google Scholar 

  • Prantera C, Pallone F, Brunetti G et al. (1992) Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn’s disease. Gastroenterology 103: 363–368

    PubMed  CAS  Google Scholar 

  • Rhodes J, Pugh S, Thomas G (1993) Have topical steroids a mture in Crohn’s disease? Eur J Gastroenterol Hepatol 5: 495–498

    Google Scholar 

  • Rutgeerts P, Hiele M, Geboes K et al. (1996) Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology 108: 1617–1621

    Article  Google Scholar 

  • Schreiber S, Howaldt S, Raedler A (1994) Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn’s ileocolitis. Gut 35: 1081–1085

    Article  PubMed  CAS  Google Scholar 

  • Steinhart AH, Hemphill D, Greenberg GR (1994) Sulfasalazine and mesalazine for the maintenance therapy of Crohn’s disease: a meta-analysis. Am J Gastroenterol 89: 2116–2124

    PubMed  CAS  Google Scholar 

  • Tromm A, Möllmann HW, May B (1996) Praxis der Glukokortikoidtherapie ch ronisch entzündlicherDarmerkrankungen. In: May B, Möllmann HW (Hrsg) Glukokortikoidtherapie chronisch entzündlicher Darmerkrankungen. Falk Foundation e.V., Freiburg S9–26

    Google Scholar 

Therapieempfehlungen bei Morbus Crohn

  • Buckley M, O’Morain C (1994) Salicylates, steroids and immunosuppressants in Crohn’s disease. Eur J Gastroenterol Hepatol 6: 85–92

    Google Scholar 

  • Rutgeerts PJ (1994) Prevention of early recurrence of Crohn’s disease after ileal resection with ileocolonic anastomosis. Eur J Gastroenterol Hepatol 6: 113–116

    Article  Google Scholar 

  • Salomon S, Kornbluth A, Alsenberg J et al. (1992) How effective are current drugs for Crohn’s disease? J Clin Gastroenterol 14: 211–215

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik, Universität Ulm, Robert-Koch-Str. 8, 89081, Ulm, Germany

    Prof. Dr. Guido Adler

Authors
  1. Prof. Dr. Guido Adler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Adler, G. (1996). Medikamentöse Therapie des Morbus Crohn. In: Morbus Crohn - Colitis ulcerosa. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-61023-3_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-61023-3_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64661-4

  • Online ISBN: 978-3-642-61023-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation